Spyre Therapeutics said it is deprioritizing its anti-TL1A rheumatoid arthritis antibody SPY072 after Phase 2 monotherapy results missed its success bar. The company framed the decision as a shift away from a less competitive clinical posture, while acknowledging the broader challenges faced by cytokine-targeting approaches in RA. The update follows parallel readouts for TL1A programs that are being tested across immune-mediated indications, but the RA dataset appears insufficient to support continued monotherapy investment. The disclosure also highlights how investors and development teams are tightening internal thresholds as more targeted immunotherapies show mixed differentiation. For the sector, the practical takeaway is that even well-defined immune targets can struggle to deliver durable, clinically meaningful endpoints in complex chronic disease when safety and efficacy tradeoffs don’t align.